Kaveri Pohlman: Got it. That’s very helpful. And then I believe for ovarian cancer results, you mentioned that you have completed the enrollment. But can you tell us how long these patients have been on treatment? And will you be able to provide any results on durability?
Jay Short: Well, these have started some time ago, and I maybe allow Eric to give better feedback on the timeline. But I’ll just remind everyone, these are IIT studies. So the actual — we’re waiting on the data ourselves. So we’re — we know it is not too far off in the future. We’ve been told by IT studies. We know they’re fully enrolled, so we should have a nice snapshot. But Eric, maybe you want to get a sense when things started keeping in mind that all the patients have come on board at different times. So it’s hard to give a specific number. But Eric, do you want to add some more color to it?
Eric Sievers: Jay, I think you’ve characterized that really well. We started working with the Canadian clinical trials group back in 2020 about this. Then we had a mature protocol and started enrolling patients at different times in the 2 different protocols. I mean, the 2 different regimens, one for the RORI asset and the other for AXL. We are looking forward to seeing these data as well.
Jay Short: I think we’ll get some insight on the durability. Obviously, the latter patients in that study will have a little less than the earlier ones, but that’s the way it works.
Kaveri Pohlman: Got it. And maybe a last one. Besides exploring the dosing schedule, do you also plan to continue to explore Axel expression score for each tumor type to confirm the patient population that responds best to the treatment? And any changes you expect or need to make in terms of your companion diagnostic tests?
Jay Short: I think the companion diagnostics path forward was in good shape. I would just say though, we — I think we reported out earlier in the year that we had at least 1 PR at the 1% TMPS score level at lung. So we are exploring a bit further without getting into too many details at this point. But yes, that’s certainly on our mind, and we’re evaluating things.
Kaveri Pohlman: Thank you.
Operator: And our next question is from Arthur He with H.C. Wainwright.
Arthur He: I had a – so for the 371 data update. So could you give us the current 5 mg per kilo in combo? What’s the average cycle of the 3 that we want to be dosed?
Jay Short: It can’t be very long because I think we reported out that we were just losing them in our kind of May time frame, something like that. And June, I think also at some of the conferences we may have mentioned in June. So can only expect it to be a few months. But I think that in general, we’re encouraged with what we’re seeing.
Arthur He: Okay.
Jay Short: And by the way, Arthur, I should add, though, but we have earlier at those levels that just happened to be earlier and several of those have gone on for quite some time, well over the 3 to 4 cycles that are normally attainable.
Arthur He: I see. I see, yes. And for the 10 mg per kilo, is there in the monotherapy dosing stage or it’s already reached the combo dosing?
Jay Short: I think it’s — we don’t have a precise — I know one has made it, but I don’t have much more information and I don’t know the status. But so let’s — that’s about all we’re going to give right now. We just see how plays here.
